Primary human hepatocytes (PHHs) are a limited resource for drug screening, their quality for in vitro use can vary considerably across different lots, and a lack of available donor diversity restricts our understanding of how human genetics affect drug-induced liver injury (DILI). Induced pluripotent stem cell-derived human hepatocyte-like cells (iPSCHHs) could provide a complementary tool to PHHs for high-throughput drug screening, and ultimately enable personalized medicine. Here, we hypothesized that previously developed iPSC-HH-based micropatterned co-cultures (iMPCCs) with murine embryonic fibroblasts could be amenable to long-term drug toxicity assessment. iMPCCs, created in industrystandard 96-well plates, were treated for 6 days with a set of 47 drugs, and multiple functional endpoints (albumin, urea, ATP) were evaluated in dosed cultures against vehicle-only controls to enable binary toxicity decisions. We found that iMPCCs correctly classified 24 of 37 hepatotoxic drugs (65% sensitivity), while all 10 non-toxic drugs tested were classified as such in iMPCCs (100% specificity). On the other hand, conventional confluent cultures of iPSC-HHs failed to detect several liver toxins that were picked up in iMPCCs. Results for DILI detection in iMPCCs were remarkably similar to published data in PHH-MPCCs (65% versus 70% sensitivity) that were dosed with the same drugs. Furthermore, iMPCCs detected the relative hepatotoxicity of structural drug analogs and recapitulated known mechanisms of acetaminophen toxicity in vitro.
models including microsomes, cell lines, primary human hepatocytes (PHHs), and liver slices are used to supplement animal testing (Guillouzo, 1998) . However, microsomes cannot be used to evaluate drug toxicity; cell lines display abnormal morphology and levels of liver functions (Gerets et al., 2012; Wilkening et al., 2003) ; and, liver slices suffer from limited viability and are not amenable to high-throughput screening. Thus, PHHs are considered ideal for drug metabolism and toxicology assessments because they retain phenotypic functions for several weeks in vitro when subjected to appropriate culture conditions (Godoy et al., 2013; Khetani and Bhatia, 2008) . Nevertheless, the paucity of healthy liver tissue and significant lot-to-lot variability in phenotypic functions impedes the use of PHHs for screening the toxic potential of large (millions) compound libraries in early drug discovery, where structure-activity relationship approaches are still feasible. Furthermore, a lack of available PHH donor diversity makes it difficult to explore the genetic basis of DILI.
Induced pluripotent stem cell-derived human hepatocyte-like cells (iPSC-HHs) could provide an unlimited supply of cells for building sustainable and high-throughput culture models for drug screening (Scott et al., 2013) . However, it is widely accepted that iPSC-HHs generated using temporal delivery of growth factors and extracellular matrices (ECMs) alone have very low and declining functions (ie, CYP450 activities) relative to adult PHHs (Gerbal-Chaloin et al., 2014; Schwartz et al., 2014) . Recent appraisals of drug toxicities in iPSC-HH cultures have been restricted to highly toxic compounds with acute dosings. Even then, several overtly liver toxic compounds in the clinic were not identified correctly in such cultures (Medine et al., 2013; Takayama et al., 2013) , potentially due to the very low activities of drug metabolism enzymes. Comparisons of DILI predictive power between functionally stable iPSC-HH and PHH cultures using the same drugs with diverse mechanisms of action should help spur the use of iPSC-HHs in drug toxicity assessments.
Co-culture with liver-and non-liver-derived stromal cells from multiple species has long been known to stabilize the phenotype of primary hepatocytes from human and animal livers in vitro (Bhatia et al., 1999; Guillouzo, 1998) . In particular, Khetani and Bhatia (2008) developed a micropatterned co-culture (MPCC) platform in which primary hepatocytes are organized onto collagen-coated domains of empirically optimized dimensions and subsequently surrounded by 3T3-J2 murine embryonic fibroblasts. MPCCs induce long-term liver functions in multiple species of primary hepatocytes and have been shown to predict clinical drug outcomes with significantly higher sensitivities than conventional culture models (Khetani and Bhatia, 2008; Khetani et al., 2013; Wang et al., 2010) . We recently optimized the MPCC technique for use with commercially available iPSC-HHs (iCell Hepatocytes from Cellular Dynamics International), demonstrating substantial improvements in iPSC-HH functions for at least 4 weeks in vitro when benchmarked against multiple PHH donors and in contrast to a declining liver phenotype in conventional iPSC-HH monolayers . In particular, iPSC-HHs in these so-called iPSC-HH-based micropatterned co-cultures (iMPCCs) contain an in vivo-like hepatocyte morphology and polarity, secrete albumin and urea, display activities of major CYP450 and Phase II enzymes, show drug-mediated CYP450 induction, and downregulate fetal markers (ie, alpha-fetoprotein) .
In this study, we used a set of 47 drugs to assess the sensitivity and specificity of iMPCCs for DILI prediction and compared our results with both conventional iPSC-HH monolayers created from the same iPSC-HH donor as well as previously published results in PHH-MPCCs using an identical drug set (Khetani et al., 2013) . We also demonstrated proof-of-concept in detecting donor-dependent differences in drug toxicity by using two separate donors of commercial iPSC-HHs. Furthermore, we explored the potential of iMPCCs for detecting the differential toxicity of structural drug analogs and to probe mechanisms of drug toxicity, two applications that are well suited for the drug development pipeline. In the future, iMPCCs could be useful for a first tier drug toxicity screen prior to further studies in limited PHHs. As additional iPSC-HH lines with genetically diverse backgrounds become commercially available, we anticipate that iMPCCs could be useful to elucidate mechanisms underlying inter-individual susceptibilities to drug toxicity.
MATERIALS AND METHODS
Processing of induced pluripotent stem cell-derived hepatocyte-like cells. iPSC-HHs were provided by Cellular Dynamics International (CDI, Madison, Wisconsin) and are available commercially as iCell Hepatocytes. Per information provided by CDI, iPSC-HH donor 1 is a Caucasian female whose iPSCs were originally reprogrammed from dermal fibroblasts, while iPSC-HH donor 2 is a Caucasian male whose iPSCs were originally reprogrammed from peripheral blood mononuclear cells. The iPSCHHs from donor 1 were obtained fresh in flasks, whereas iPSCHHs from donor 2 were cryopreserved in vials. Upon arrival, fresh iPSC-HHs were processed according to manufacturer-supplied protocols. In brief, iPSC-HH cell aggregates were retrieved from the cell shipment flask and pelleted via centrifugation (100 Â g for 1 min). The pellet was rinsed with divalent cationfree Hank's Balanced Saline Solution (Hyclone, South Logan, Utah) and further centrifuged at 100 Â g for 1 min. Pelleted cell aggregates were dissociated with 0.5% trypsin-EDTA (Life Technologies, Grand Island, New York) for 7 min with intermittent swirling, neutralized with a 1:1 solution of Roswell Park Memorial Institute 1640 medium (RPMI, Life Technologies) and fetal bovine serum (Life Technologies), and pelleted via centrifugation (100 Â g for 5 min) to remove the trypsin solution. Deaggregated iPSC-HHs were re-suspended in KryoThaw (SciKon Innovation, Research Triangle Park, North Carolina) and again centrifuged to remove dead cells and excess debris (100 Â g for 10 min). Finally, single iPSC-HHs were diluted in CDI's recommended plating medium, composed of RPMI, 1 lM dexamethasone, 2% (v/v) B27 (Life Technologies), 1% (v/v) penicillin/ streptomycin (Corning Life Sciences, Tewksbury, Massachusetts), and 20 ng/ml oncostatin-M (R&D Systems, Minneapolis, Minnesota). Cryopreserved iPSC-HHs vials from donor 2 were processed according to manufacturer protocols.
Fibroblast culture. Murine embryonic 3T3-J2 fibroblasts were a gift from Howard Green of Harvard Medical School (Rheinwald and Green, 1975) . Cells were cultured at 37 C, 10% CO 2 in Dulbecco's Modified Eagle's Medium (Corning Life Sciences) with high glucose, 10% (v/v) bovine calf serum (Life Technologies), and 1% (v/v) penicillin-streptomycin. Fibroblasts were passaged up to 12 times prior to use in MPCCs with iPSC-HHs.
Establishment of iPSC-HH cultures. Tissue culture polystyrene 96-well plates (Corning Life Sciences) were coated for 2 h with 25 lg/ml rat tail collagen-I (Corning Life Sciences) and rinsed twice with sterile water. Following CDI's protocols, processed iPSC-HHs were diluted to a density of 8 Â 10 5 cells/ml and seeded in collagen-coated plates (50 ll/well) to create conventional confluent monolayers (iCCs). Maintenance medium was replaced after the first 24 h and every other day thereafter.
To create iMPCCs, tissue culture polystyrene 96-well plates were coated with rat-tail collagen-I, as described above, and subjected to polydimethylsiloxane mask-based soft lithography to micropattern circular collagenous islands (500 lm diameter, 1200 lm center-to-center spacing) . iPSC-HHs were seeded at a density of 6.67 Â 10 5 cells/ml into collagen micropatterned wells (50 ll/well) (Fig. 1) . After allowing 4-5 h for cellular attachment and spreading onto collagen-coated islands, wells were washed 3Â in RPMI base medium to remove unattached cells, leaving $4500 iPSC-HHs per well in 96-well format ($14 islands/well). The iPSC-HHs that attached to collagen domains were positive for both albumin and glycogen as previously shown . 3T3-J2 fibroblasts were subsequently seeded at a density of 3 Â 10 5 cells/ml (50 ll/well) and allowed to fill the remaining area surrounding the iPSC-HH islands. Micropatterned pure iPSC-HH cultures, which did not receive murine fibroblasts (iMPHs), were used as densitymatched controls. Culture medium was changed every other day as previously described .
Hepatic morphological, functionality, and health assessments. The morphology of iPSC-HHs was monitored using an EVOSFL cell imaging system (Life Technologies) with standard 4Â, 10Â, and 20Â phase contrast objectives. Culture supernatants were assayed for albumin levels using a competitive enzyme-linked immunosorbent assay (MP Biomedicals, Santa Ana, California) with horseradish peroxidase detection and 3,3',5,5'-tetramethylbenzidine (Rockland, Boyertown, Pennsylvania) as the substrate (Khetani and Bhatia, 2008) . Urea production was measured via a colorimetric endpoint analysis with diacetylmonoxime, acid, and heat (Stanbio Labs, Boerne, Texas). CYP3A4 activity in iPSC-HH cultures was measured using the luminescence-based luciferin-IPA assay from Promega (Madison, Wisconsin) per manufacturer's instructions. ATP levels in cell lysates were quantified by CellTiter-Glo (Promega); levels in iMPCCs were subtracted from fibroblast-only controls to assess iPSC-HH-only contributions. Albumin, urea, and ATP assays were conducted on the same wells. Absorbance and luminescence for the aforementioned assays were measured using a BioTek (Winooski, Vermont) Synergy H1 tri-mode plate reader.
Drug dosing studies. After $1 week of stabilization, cultures were dosed in serum-free culture medium (ie, little to no binding of drug to protein) 3 times, every other day, at 25ÁC max and 100ÁC max (total human plasma concentration, Table 1 ). The DMSO concentration that iPSC-HH cultures were exposed to was kept at 0.1% relative to culture medium for all compounds except that 0.2% was used for five compounds (acetazolamide, cyclophosphamide, hydroxyurea, mefenamic acid, and quinine), while 1.0% was used for three compounds (phenacetin, phenylbutazone, and pyrazinamide) due to solubility issues. Compounds and dose ranges were selected from a previous study to include true positive (TP, compounds that were correctly identified as toxic in primary hepatocyte imaging assay technology [HIAT]), true negative (TN, compounds that were correctly identified as non-toxic in HIAT), and false negative (FN, compounds that were incorrectly identified as non-toxic in HIAT) compounds. All compounds were purchased from either Sigma-Aldrich (St. Louis, Missouri) or Cayman Chemical (Ann Arbor, Miami). Vehicle-only controls were maintained at each DMSO concentration listed above. For some studies, the glutathione (GSH) depleting agent L-buthionine (S,R)-sulfoximine (BSO, Sigma-Aldrich) was co-incubated at a dose of 200 lM with acetaminophen (APAP) following the same treatment schedule described above (ie, three repeat dosings over 6 days). Additional cultures were co-incubated with 
Notes. Compounds were selected from the study by where HIAT was applied to ECM-sandwich cultures of PHHs dosed for 24 h with various drugs. DILI severity scores from the LTKB (Liver Toxicity Knowledge Base) of the FDA (Chen et al., 2013) : N/A indicates not applicable/no information in the database, negative numbers indicate that drug was withdrawn from the market, and higher positive numbers indicate a greater DILI concern. DILI categorization: P1, DILI type 1, dose dependent (toxic); P2, DILI type 2, idiosyncratic (toxic); N1, not known to cause liver injury (non-toxic); N2, sporadic cases (<10) of liver injury reported but generally considered safe drug to use by doctors (non-toxic); O1, hepatotoxic in animals, untested in humans (toxic); O2, elevated liver enzymes observed in humans but does not lead to frank liver toxicity (non-toxic). Clinical classification per : considered a liver toxin (þ) or a non-liver-toxin (-). Model predictions: All models were dosed up to 100ÁC max for each compound and classified as liver toxins or non-toxins based on specific algorithms as described in methods. The HIAT-sandwich classifications are from , the PHH-MPCCs classifications are from Khetani et al. (2013) , while the iMPCC (using iPSC-HHs) classifications represent the data collected in this study.
APAP and 10 lM of the broad CYP inhibitor 1-aminobenzotriazole (ABT, Sigma-Aldrich). Controls with only BSO or ABT (ie, no APAP) were included for baseline toxicity measurement.
Data analysis. Data processing and visualization were performed using Microsoft Excel and GraphPad Prism (La Jolla, California), respectively. For each assay, data were normalized to the appropriate vehicle control, and mean and standard deviation values were calculated using 3 technical replicates for each of the drug doses administered. TC 50 values (concentration that decreased the measured endpoints by 50%) for each assay were interpolated using linear curve fitting between the dose at which the assay signal was greater than 50% of control values and the dose at which the assay signal was 50% of control values. A compound that yielded a TC 50 value 100ÁC max for any one of the three assays was classified as 'toxic', while a compound that had TC 50 values >100ÁC max (ie, could not be interpolated within the dose range tested) for all three assays was classified as 'non-toxic'. Sensitivity was defined as the fraction of correctly predicted positive toxins to all positive toxins in the clinic 
RESULTS
Functional maturity and stability of the iMPCC platform Khetani and Bhatia have previously developed a MPCC platform in which primary hepatocytes are organized onto collagencoated islands of empirically optimized dimensions and subsequently surrounded by 3T3-J2 murine embryonic fibroblasts (Khetani and Bhatia, 2008) , now known to induce robust functions in hepatocytes from multiple species (Ukairo et al., 2013a) . We have adapted and optimized the MPCC technique for culture with iPSC-HHs, commercially available as iCell Hepatocytes by Cellular Dynamics International or CDI (Fig. 1 ). Liver functions (albumin secretion, urea synthesis, CYP3A4 activity) in these so-called iMPCCs (500 lm diameter, 1200 lm center-to-center spacing) were found to be significantly higher and stable for 4 weeks as compared with a declining phenotype in densitymatched micropatterned pure iPSC-HH (iMPH) monolayers ( Supplementary Fig. 1A-C) . Furthermore, iPSC-HHs in iMPCCs displayed prototypical polygonal hepatic shape, distinct nuclei/ nucleoli, and presence of bile canaliculi between cells. On the other hand, iPSC-HHs looked 'de-differentiated' (ie, spread out) in pure monolayers without fibroblasts after a week in culture (Supplementary Fig. 1D and E). The stability of iMPCCs allowed us to carry out the repeat drug treatment protocol as described in subsequent sections. In addition to the aforementioned dataset, liver gene expression and functions (including major CYP450 enzymes and Phase II conjugation) have been more extensively characterized in iMPCCs in another recent publication , and were shown to be significantly higher and more stable for at least 4 weeks when compared with declining functions in commonly employed conventional confluent monolayers. In brief, analysis of iMPCC whole genome microarrays by CellNet (Cahan et al., 2014) , a network biology platform used to evaluate the fidelity of engineered cells by measuring the establishment of tissue-specific gene regulatory networks (GRNs), classified iMPCCs as exclusively liver, with liver-specific GRN scores that fell within the range of scores obtained for two freshly isolated PHH donors. Albumin secretion by iMPCCs was within the range of donor diversity observed in PHH-MPCCs, while urea production was $30-50% of PHH-MPCCs. CYP450 activity levels in iMPCCs ranged from $5% (CYP2C19) to $70% (CYP1A2) of PHHMPCCs. We showed up to $90% CYP3A4 activity in iMPCCs relative to conventional 24 h-old PHH cultures and $40-55% relative to functionally stable PHH-MPCCs from multiple donors. Finally, the albumin to alpha-fetoprotein protein ratio in iMPCCs increased from 7.2 on day 11 to 12.2 on day 21 of culture, thereby demonstrating improving maturity of iPSC-HHs over time.
Compound selection, culture dosing, and criteria for toxicity decisions We selected 47 compounds from a previously published study in which conventional sandwich-cultured PHHs were dosed with compounds for 24 h followed by analysis via hepatocyte imaging assay technology (HIAT) to assess organelle dysfunctions (ie, mitochondrial membrane potential, reactive oxygen species) . Thirteen of these compounds were reported as DILI positive (TPs), meaning that hepatotoxicity was observed for these drugs in HIAT at a concentration at or below 100ÁC max (maximum plasma concentration reported for humans). Ten drugs did not elicit hepatotoxicity in HIAT at test concentration of 100ÁC max and are also considered safe in humans (TNs). Another 24 DILI compounds were not identified as toxic utilizing HIAT, but are known to cause clinical DILI (FNs). In addition, PHH-MPCCs have been previously dosed over 5-9 days with these same compounds and binary decisions on toxicity potential have been published (Khetani et al., 2013) . Here, we sought to compare drug responses in iMPCCs relative to PHH-based models used in these previously published studies.
Preliminary investigations using nine compounds (APAP, amiodarone, aspirin, dextromethorphan, diclofenac, propranolol, rosiglitazone, troglitazone, and warfarin) revealed that the sensitivity in iMPCCs to be the highest while maintaining 100% specificity after 6 days of dosing (three drug treatments administered every other day) based on the TC 50 criteria described below. Albumin, urea, and ATP levels were assessed in iMPCCs using the same wells. While albumin and urea are liver-specific markers and are not secreted by the 3T3-J2 fibroblasts used here, ATP is present in both cell types and thus fibroblast-only control cultures were carried out alongside iMPCCs to determine effects of drugs on iPSC-HHs in particular. Since intracellular GSH was previously found to be less sensitive for binary DILI prediction in PHH-MPCCs (Khetani et al., 2013 ), it was not tested in iMPCCs here. That being said, GSH levels can prove to be useful in a more investigative scenario where drug bioactivation is suspected to be the mechanism of toxicity. Sample drug dose responses in iMPCCs for hepatotoxins and non-liver-toxins are shown in Figure 2 .
The DMSO concentration that iPSC-HH cultures were exposed to was kept at 0.1% (v/v) relative to culture medium for 39 of 47 compounds tested, while 0.2% was used for five compounds, and 1.0% was used for three compounds due to solubility issues (Table 1) . Increasing levels of DMSO in culture medium, as expected from previously published data (Easterbrook et al., 2001) , did indeed cause a reduction in CYP3A4 activity in the cultures ($8% reduction at 0.1% DMSO concentration, $25% at 0.2%, and $40% at 1%) (Supplemental Fig. 2) . However, appropriate control cultures at each DMSO concentration were used to normalize data from drug-dosed cultures in order to enable binary decisions as described below. A compound was declared 'toxic' if the TC 50 , the drug concentration that reduces endpoint functional activity to 50% of vehicle-only controls, was at or below 100ÁC max for at least one of the multiplexed assays on iMPCCs. If the TC 50 value was >100ÁC max for all three multiplexed assays (ie, could not be interpolated from dose range tested), the compound was considered 'non-toxic'. Table 1 provides the C max values, formula weights, known clinical DILI classifications, and toxic/ non-toxic decisions in iMPCCs relative to published information using PHH-MPCCs and the HIAT assay. If applicable, the DILI severity score from the Liver Toxicity Knowledge Base (LTKB), provided by the FDA, appears in the respective column of Table 1 . C max values for these compounds varied widely across the entire set, from 0.004 mM for betahistine 2HCl to 793.9 mM for hydroxyurea.
DILI TP compounds
C max values for the 13 TP compounds used in this study varied from 0.126 mM for mebendazole to 486.8 mM for phenylbutazone. Figure 3A provides the interpolated TC 50 values for these compounds as calculated by albumin and urea, two critical functions of the liver which have been recently shown to be as sensitive for DILI detection in PHHs in vitro as more conventional endpoints such as ATP and GSH (Khetani et al., 2013) . Furthermore, albumin and urea can be monitored in cell culture supernatants over time without the need to lyse the cultures. We found that iMPCCs, similar to PHH-MPCCs and the HIAT assay, correctly detected all 13 TP compounds as 'toxic' based on the TC 50 algorithm described above. Urea production by iMPCCs was reduced by at least 50% following administration of all 13 compounds, while albumin secretion was reduced by at least 50% following administration of 12 of the 13 compounds (flurbiprofen being the exception). ATP (data not shown) was reduced by at least 50% by 10 of 13 compounds (except flurbiprofen, mebendazole, troglitazone). Thus, as with PHH-MPCCs, ATP data in iMPCCs proved to be less sensitive than albumin and urea secretion for DILI detection.
DILI TN compounds
C max values of the TN compounds tended to be lower than those for the TP compounds and ranged from 0.005 mM for buspirone to 5.526 mM for aspirin. None of the 10 TN compounds tested showed a 50% or greater reduction in albumin, urea, or ATP in iMPCCs. Hence, all were correctly identified as 'non-toxins' in all three models that were compared (iMPCCs, PHH-MPCCs, and HIAT). Therefore, the specificity of the iMPCC assay was not lower than the aforementioned PHH-based models.
DILI FN compounds
C max values for the 24 FN compounds ranged from 0.004 mM for betahistine 2HCl to 793.9 mM for hydroxyurea. Eleven of the 24 FN compounds caused at least a 50% reduction in at least one or more of the markers (albumin, urea, or ATP) evaluated in iMPCCs. TC 50 values from the iMPCC albumin and urea data are presented graphically in Figure 3B . Ciprofloxacin HCl and piroxicam caused reductions in all three parameters while clomipramine, cyproterone acetate, and tamoxifen caused reductions in albumin and urea. Hydroxyurea was the only compound that led to reductions in both albumin and ATP, but not urea, likely due to its interference with the urea assay. Albumin was the only marker reduced by at least 50% following dosing of iMPCCs with cyclophosphamide, isoniazid, and pyrazinamide. Urea was the only marker reduced by at least 50% following dosing of iMPCCs with imipramine HCl and nortriptyline HCl.
Comparison of drug toxicity in iMPCCs with other models
For the drugs that were correctly identified as 'toxic' in both iMPCCs and in PHH-MPCCs from a previous publication (Khetani et al., 2013) , we compared TC 50 values for albumin secretion in both models (Supplementary Table 1 ). Twelve of these 21 compounds led to albumin TC 50 values higher in iMPCCs relative to PHH-MPCCs, while nine compounds had albumin TC 50 values higher in PHH-MPCCs relative to iMPCCs. Albumin secretion in PHH-MPCCs (but not in iMPCCs) was not reduced by at least 50% in response to cyproterone acetate, isoniazid, and phenacetin within the dose range tested (ie, no TC 50 for albumin could be interpolated). However, PHH-MPCCs were able to correctly identify three 'toxic' FN drugs that were missed in iMPCCs: acetazolamide, dapsone, and maleic acid ( Table 1) . The aforementioned differences between iMPCCs and PHHMPCCs in drug toxicity outcomes could potentially be due to donor-dependent phenomena. Indeed, when we dosed PHHMPCCs created from another donor with acetazolamide, dapsone, and maleic acid, we found that only dapsone was called 'toxic' based on the aforementioned algorithm, while the other two compounds were called 'non-toxic' (Supplementary Table  2 ). Interestingly, piroxicam was picked up in iMPCCs containing donor 1 iPSC-HHs, but not in PHH-MPCCs, which further suggests donor-dependent differences.
Next, we selected 13 drugs (TP or FN) that were picked up as toxins in iMPCCs to test on conventional confluent iPSC-HH cultures (iCCs, created per protocols from Cellular Dynamics International) from the same donor cells. Five of these 13 compounds failed to show toxicity in iCCs ($38% reduction in sensitivity, Supplementary Table 3 ). For instance, phenacetin was picked up in the HIAT assay using PHHs , PHHMPCCs (Khetani et al., 2013) , and iMPCCs here, but not using the iCC model. Table 2 , iMPCCs and PHH-MPCCs had sensitivities of 65% and 70%, respectively, for the 37 hepatotoxic compounds tested. Both models correctly identified all 10 non-liver-toxins and thus had a specificity of 100%. 
Overall sensitivity and specificity at TC 50 We define model sensitivity as the portion of clinical hepatotoxins correctly identified as 'toxic' in vitro ([TP]/[TP þ FN]), while the specificity as the portion of non-liver-toxic compounds correctly identified as 'non-toxic' in vitro ([TN]/[TN þ FP]). As detailed in

Comparison of TC 50 values across iPSC-HH donors in iMPCCs
iPSC-HHs from a second donor were incorporated in the iMPCC platform (see 'Materials and Methods' section) and the cultures were dosed for 6 days with all 24 drugs correctly classified as 'liver toxins' with the first iPSC-HH donor and five non-toxic control drugs. The albumin and urea TC 50 values for the two donors are shown in Table 3 . While there are differences in the TC 50 values across the two donors as expected, both donors correctly classified 22 of the 24 drugs as liver toxins as well as five of the five drugs as non-toxins. Donor two was not able to correctly classify two of the 24 drugs as liver-toxins, namely phenacetin and piroxicam.
Structural drug analogs and bio-activation of APAP When treated with structural drug analogs, the iMPCC platform was able to distinguish differences in toxicity between known hepatotoxins and their less toxic analogs. Figure 4A shows albumin secretion in iMPCCs treated with increasing doses of tolcapone (hepatotoxic) or entacapone for up to 96 h. Only tolcapone led to a severe decline in iMPCC albumin secretion with time and dose, whereas albumin secretion remained relatively steady when iMPCCs were treated with entacapone. A similar trend was observed with analogs, troglitazone (hepatotoxic), and rosiglitazone (Fig. 4B ).
To probe drug bioactivation, iMPCCs were co-incubated with APAP and compounds that are known to impact the metabolic pathways of APAP. When iMPCCs were treated with both the GSH depleting agent, L-buthionine (S,R)-sulfoximine or BSO, and multiple doses of APAP, they experienced a significantly greater decline in albumin secretion than when treated with APAP alone (Fig. 5A) . On the other hand, treating iMPCCs with both the broad CYP inhibitor, 1-aminobenzotriazole or ABT, and APAP led to a reduction in toxicity (ie, increase in albumin output) than when treated with APAP alone (Fig. 5B) . Neither BSO nor ABT alone led to down-regulation of albumin secretion in iMPCCs (data not shown). The aforementioned results suggest that APAP toxicity in iMPCCs occurs through CYP450-mediated formation of a reactive metabolite that is subsequently detoxified via GSH, as observed both in vitro in primary hepatocytes (Ukairo et al., 2013b) and in vivo in rodents (David Josephy, 2005) .
DISCUSSION
In contrast to a limited supply of PHHs, iPSC-HHs could provide a nearly unlimited number of cells for screening compound libraries in early drug discovery where structure-activity relationships can aid in the design of safer and more efficacious drugs. These cells could also enable a better understanding of inter-individual susceptibility to drugs, including mechanisms underlying idiosyncratic drug toxicity (Scott et al., 2013) . We have recently shown that when housed in an MPCC format with murine embryonic fibroblasts (iMPCCs), iPSC-HHs from multiple donors display significantly greater levels and stability of major liver functions (ie, CYP450 activities) for $4 weeks as opposed to a declining phenotype in conventional iPSC-HH monolayers . Here, we showed that the predictive power for DILI assessment in iMPCCs was remarkably similar (65-70% sensitivity, 100% specificity) to their PHH-MPCC counterparts (Table 1) . Furthermore, we also demonstrated iMPCC utility in assessing donor-dependent differences in drug toxicity outcomes, detecting differential toxicity of structural drug analogs, and probing bioactivation mechanisms underlying DILI using APAP.
We chose 47 drugs from different classes that have previously been tested in sandwich-cultured PHHs using HIAT and PHH-MPCCs (Khetani et al., 2013) . Given the variable drug concentrations observed in human blood, partially attributed to polymorphisms in hepatic drug metabolism enzymes and transporter proteins, drug doses up to 100ÁC max were selected as justified previously . Nonetheless, our dose selection here enabled quantitative comparisons between iPSC-HH responses and those observed with PHHs in the aforementioned studies. As with PHH-MPCCs, liver dysfunction in iMPCCs was assessed via albumin and urea secretion in supernatants, while overall viability was assessed using ATP in cell lysates. The 3T3-J2 fibroblasts did not secrete albumin and urea, while ATP levels in iMPCCs were $2-fold higher than in fibroblast-only controls. Select compounds were used to first optimize the timing of dosing (three drug doses over 6 days) such that sensitivity was improved without compromising high specificity. A drug was called 'toxic' if a TC 50 Note. "N/A" indicates that a TC 50 value (the interpolated concentration at which cell function decreases by 50% of respective DMSO-only controls) was above 100ÁC max for a given endpoint and therefore could not be calculated from the dose range used. Bolded compounds are those for which neither of the two endpoints could be used to interpolate a TC 50 value in donor #2.
value could be interpolated for any of the three endpoints within the dose range tested, while the drug was called 'nontoxic' if none of the endpoints yielded an interpolated TC 50 value. All 13 TP compounds were correctly identified in iMPCCs. Urea production was the most sensitive endpoint (13 of 13 compounds), followed by albumin (12 of 13) and ATP (9 of 13). Furthermore, none of the 10 TN compounds caused a reduction of !50% in any endpoint. Thus, non-destructive measurement of albumin and urea in medium can suffice for an initial dose-and time-dependent assessment of drug toxicity in both iMPCCs and PHH-MPCCs (Khetani et al., 2013) . Other parameters (ie, GSH, high content imaging of organelle dysfunctions) can subsequently be used for a mechanistic exploration of hepatotoxicity. The 100% sensitivity for TP compounds and 100% specificity for TN compounds observed in iMPCCs were consistent with studies using PHH cultures (Khetani et al., 2013; .
From the 24 FN compounds, 11 were detected as toxic in iMPCCs. For these compounds, albumin secretion was the most sensitive endpoint (9 of 11 compounds), followed by urea (7 of 11) and ATP (3 of 11). Two compounds (ciprofloxacin, piroxicam) caused a !50% reduction in all three markers, while four others (clomipramine, cyproterone acetate, hydroxyurea, and tamoxifen) caused a reduction in two markers. Hydroxyurea was the only compound to be identified as toxic with ATP and albumin; however, this compound interfered with the urea assay. When the 13 compounds correctly identified as toxic in iMPCCs were also tested in conventional confluent iPSC-HH monolayers from the same donor, five (cyproterone acetate, phenacetin, isoniazid, pyrazinamide, and tamoxifen) failed to show toxicity, leading to a $38% reduction in sensitivity. Thus, the iMPCC platform improved the sensitivity for drug toxicity detection in iPSC-HHs over conventional monolayers.
Drugs tested here cause hepatic injury through diverse mechanisms such as toxic metabolites that deplete GSH and bind macromolecules (ie, APAP), dissipate mitochondrial membrane potential (ie, troglitazone), accumulate within mitochondria (ie, amiodarone), induce steatosis (ie, amiodarone), and inhibit transporters (ie, clozapine) (Grattagliano et al., 2009; Yuan and Kaplowitz, 2013) . Here, we showed GSH depletion and bioactivation as potential mechanisms underlying APAP toxicity in iMPCCs, which is consistent with in vitro studies using primary hepatocytes (Ukairo et al., 2013b ) and APAP's known mode of action in vivo (David Josephy, 2005) . Furthermore, consistent with other studies in cell lines and PHHs (O'Brien et al., 2006; Tolosa et al., 2012; , we found that some idiosyncratic toxins (ie, troglitazone, isoniazid) could be properly classified using cellular stress markers in iMPCCs, potentially because such hepatic stress is a first step in the cascade of mechanisms that cause overt liver injury in specific patients (as opposed to adaptation and recovery in others) with one or more co-varying factors such as genetics, disease, and environmental stimuli.
The sensitivity for drug toxicity detection in iMPCCs was 65% versus 70% in PHH-MPCCs and $35% with HIAT. Three compounds (acetazolamide, dapsone, and maleic acid) were correctly identified as toxic by PHH-MPCCs, but not iMPCCs. However, dosing of PHH-MPCCs from another donor using these compounds correctly classified only dapsone. Furthermore, piroxicam was detected correctly as toxic in iMPCCs, but not in PHH-MPCCs. We also tested 29 drugs in iMPCCs created using cryopreserved iPSC-HHs from a second donor in order to demonstrate proof-of-concept of on-demand and multi-donor screening. While there were differences in the TC 50 values for the endpoints, the binary calls for 27 of 29 drugs were consistent across the two donors. The two exceptions were phenacetin and piroxicam, which were not detected as toxins in the second donor even though liver functions in iMPCCs were within the range expected (data not shown). Thus, the aforementioned donor-dependent differences illustrate the need to test several donors in a prospective drug screening campaign. With rapid advances in iPSC technology, multiple donors of iPSC-HHs that reflect some genetic diversity seen in humans are likely to become available commercially and thus could be used to better understand inter-individual susceptibilities to drug toxicity.
Even though iMPCCs improved the sensitivity of drug toxicity detection over conventional cultures of both iPSC-HHs and PHHs, they did not pick up $35% of the liver toxins tested. Such FNs could be due to interaction of hepatocytes with liver stroma (ie, endothelia, Kupffer macrophages) and/or the adaptive immune system, extra-hepatic events, and genetic polymorphisms across different donors (Chen et al., 2014; Yuan and Kaplowitz, 2013) . Nonetheless, we have designed iMPCCs to be modular in that interactions between different donors of iPSCHHs and donor-matched stromal cells can be studied without significant changes to iPSC-HH homotypic interactions on the micropatterned ECM domains.
Limited in situ cell observation by conventional microscopy and nutrient transport limitations makes high-throughput screening in 3D iPSC-HH cultures (Nagamoto et al., 2012; Ogawa et al., 2013; Takayama et al., 2013; Takebe et al., 2013) non-trivial. Flowing medium can mitigate the nutrient transport limitations; however, inclusion of a flow circuit for each well generally introduces complexities in liquid handling and larger media volumes with increasing quantities of novel compounds (Yum et al., 2014) . Thus, static 2D hepatic monolayers are widely favored in industrial settings (Godoy et al., 2013) , not only for the aforementioned reasons, but when engineered with controlled homotypic and heterotypic interactions, monolayers provide for some of the highest functional levels, longevity, and accurate prediction of clinical outcomes reported to date (Khetani and Bhatia, 2008; Khetani et al., 2013; Kidambi et al., 2009; Wang et al., 2010) . While MPCCs enable a more in vivo-like hepatic morphology as opposed to flattened out (de-differentiated) hepatocytes, it is a monolayer platform amenable to high content imaging (Trask et al., 2014) , which has proven useful for understanding effects of drugs on key organelles implicated in DILI (Sirenko et al., 2014; . That being said, a new generation of micro-dispensers and micro-pumps are being designed to enable high-throughput and automated microfluidics for human-on-a-chip platforms (Yum et al., 2014) . Thus, inclusion of iMPCCs into a microfluidic device in order to understand the effects of crosstalk with other organs-on-a-chip on drug toxicity outcomes is a worthwhile endeavor we are pursuing.
In conclusion, iMPCCs have sensitivity and specificity for drug toxicity detection comparable to PHH-MPCCs and significantly higher than conventional confluent cultures of both iPSC-HHs and PHHs. The iMPCCs were also able to distinguish between known hepatotoxins and less toxic drug analogs, and demonstrate known in vivo mechanisms underlying APAP toxicity. None of the published platforms for iPSC-HH maturation (Gerbal-Chaloin et al., 2014; Schwartz et al., 2014) , including iMPCCs, fully mature iPSC-HHs toward adult PHHs. However, with advances in commercial scale differentiation and manufacturing protocols and engineered culture models such as iMPCCs, the use of more functionally mature iPSC-HHs in predictive drug screening is now feasible. More broadly, we anticipate that iMPCCs, created from multiple donors, could prove useful for modeling mechanisms underlying patient-specific DILI and other diseases.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci. oxfordjournals.org/. Albumin secretion, (B) urea production, and (C) CYP3A4 activity of iMPCCs and micropatterned iPSC-HHs without 3T3-J2 fibroblasts (iMPHs) over 4 weeks in culture.
All error bars represent standard deviations (n = 3). (D) iMPCC and (E) iMPH island morphology after 14 days in culture. Scale bars = 400 µm. Additional characterization of iMPCCs at the gene expression and functional levels is provided in another publication . in iMPCCs. After about 1 week of stabilization, iMPCCs were treated with DMSO in serum-free culture medium for 6 days. DMSO concentrations (vol/vol %) were chosen to parallel those used for drug toxicity dosing (see Table 1 of main manuscript). CYP3A4 activity was quantified using the luminescence-based luciferin-IPA assay from Promega (Madison, WI). All error bars represent standard deviations. indicates hepatocyte imaging assay technology applied to sandwich cultured primary human hepatocytes . "N/A" indicates that a TC 50 value (the interpolated concentration at which activity decreases by 50% of DMSO-only controls) was above 100·C max and therefore could not be calculated based on the dose range tested. Note that for PHH-MPCCs, where TC 50 for albumin could not be interpolated (i.e. N/A), the compound was still called a toxin based on TC 50 for urea secretion (not shown). 
